This page lists clinical trials for treating West Nile virus disease as a service to medical providers and the public and does not imply CDC endorsement of the entity conducting the study or the drug under investigation. The order of the studies below reflects the timing of their admission to the list only. To gain more information about any of these clinical trials, follow the website link associated with the study description.

Studies included on the list below must meet the following ethical and scientific criteria:

Institutional Review Board (IRB) approved
Randomized
Double-blinded
Placebo-controlled

The following studys have met these criteria:

1. A Randomized Double-Blinded, Placebo Controlled Trial of Alpha-Interferon (Alferon) Therapy for West Nile Meningoencephalitis (Protocol WN-102).
   Contact: James J. Rahal, MD, Tel. (718)-670-1525, email: JJR9002@nyp.org
   Website: http://www.nyhq.org/posting/rahal.html
2. A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of MGAWN1 in Subjects With Suspected Central Nervous System Infection Due to West Nile Virus.
   Contact: Lara Blake Tel. (301)-354-3819, email: wnv@macrogenics.com
   Website: http://clinicaltrials.gov/ct2/show/NCT00927953 and http://www.macrogenics.com/products-MGAWN1.html

To submit information about additional clinical trials for possible inclusion on this page, please contact CDC's Division of Vector-Borne Infectious Diseases at (970) 221-6400.